Dova Pharmaceuticals entered into a co-promotion agreement with Bausch Health subsidiary Salix Pharmaceuticals, the Triangle Business Journal reports.
Here's what you should know:
1. Salix and Bausch are providing 100 sales specialists to Dova to promote Dova's Doptelet.
2. Doptelet treats low blood platelet counts in adults with chronic liver disease. Doptelet is the first thrombopoietin receptor agonist approved in the U.S.
3. Through the agreement, Dova will pay Bausch a portion of its quarterly sales and a benchmark bonus of $2.5 million if certain conditions are met.
4. Dova Pharmaceuticals President and CEO Alex Sapir said, "Given Salix's presence and strong reputation within large gastroenterology group practices coupled with the early interest we are seeing among the gastroenterology community, we are excited to see the impact this partnership will bring to Doptelet and to patients."